Aster Capital Management’s Summit Therapeutics SMMT Stock Holding History

Aster Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-91	Closed	-$1.75K	–	1226
2026 Q1	$1.75K	Buy	+91	New	+$1.47K	﹤0.01%	760
2025 Q4	–	Sell	-867	Closed	-$17.9K	–	1395
2025 Q3	$17.9K	Sell	867 -558	-39%	-$13.5K	0.01%	676
2025 Q2	$30.3K	Sell	1,425 -31,084	-96%	-$709K	0.01%	661
2025 Q1	$673K	Buy	32,509 +32,229	+11,510%	+$647K	0.12%	230
2024 Q4	$5K	Buy	280 +83	+42%	+$1.61K	﹤0.01%	857
2024 Q3	$4.31K	Buy	+197	New	+$2.75K	﹤0.01%	924

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Aster Capital Management's SMMT Position: Q2 2026 in Review

Aster Capital Management sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 91 shares — an estimated $1.75K sold.

Aster Capital Management first reported a position in SMMT in Q3 2024 and held it in 6 quarters. The position peaked at $673K in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Aster Capital Management reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
Aster Capital Management sold 91 Summit Therapeutics shares in Q2 2026, an estimated $1.75K.
Aster Capital Management first reported a position in Summit Therapeutics in Q3 2024 and held it in 6 quarters.
Aster Capital Management's Summit Therapeutics position peaked at $673K in Q1 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.